Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk

verfasst von: Yonggang Zhang, Qingyi Jia, Pei Xue, Yuqi Liu, Tianyuan Xiong, Jiqiao Yang, Chenxi Song, Qing He, Liang Du

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The -786T > C polymorphism in NOS3 gene may affect the DNA repair pathways and be associated with risk of cancer. However, the results of previous studies are inconsistent. The objective of this study is to investigate the association between the -786T > C polymorphism in NOS3 and risk of cancer by meta-analysis. We searched PubMed, Embase, CNKI, and Wanfang databases and the last search was updated on Sept. 20, 2013. Statistical analysis was performed using Revman4.2 and Stata10.0 software. A total of 9 case–control studies concerning 4,089 cases and 3,847 controls were included. The results suggested a significant association between the -786T > C polymorphism in NOS3 and cancer risk (CC vs. TT + CT; OR = 1.30, 95 % CI = 1.07–1.57, P = 0.007) in total analysis. In the subgroup analysis by ethnicity and cancer types, significant associations were found in the breast cancer subgroup (OR 1.51, 95 % CI 1.07–2.12; P = 0.02) and European subgroup (OR 1.26, 95 % CI 1.01–1.58; P = 0.04). The current meta-analysis suggested that the -786T > C polymorphisms in NOS3 may be a risk factor for cancer. In the future, more case–control studies are needed to validate our results.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J Clin. 2011;61(2):69–90. doi:10.​3322/​caac.​20107.
4.
Zurück zum Zitat Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, Pagenstecher C, et al. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case–control study. Lancet Oncol. 2005;6(8):566–72. doi:10.1016/S1470-2045(05)70253-9.PubMedCrossRef Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, Pagenstecher C, et al. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case–control study. Lancet Oncol. 2005;6(8):566–72. doi:10.​1016/​S1470-2045(05)70253-9.PubMedCrossRef
5.
Zurück zum Zitat Yang X, Li B, Si T, Liu Y, Guo Z. Association between the 8473T > C polymorphism of PTGS2 and prostate cancer risk: a meta-analysis including 24,716 subjects. Onkologie. 2013;36(4):182–6. doi:10.1159/000349951.PubMedCrossRef Yang X, Li B, Si T, Liu Y, Guo Z. Association between the 8473T > C polymorphism of PTGS2 and prostate cancer risk: a meta-analysis including 24,716 subjects. Onkologie. 2013;36(4):182–6. doi:10.​1159/​000349951.PubMedCrossRef
7.
Zurück zum Zitat Ouyang FD, Yang FL, Chen HC, Khan MA, Huang FM, Wan XX, et al. Polymorphisms of DNA repair genes XPD, XRCC1, and OGG1, and lung adenocarcinoma susceptibility in Chinese population. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):2843–8. doi:10.1007/s13277-013-0844-6.CrossRef Ouyang FD, Yang FL, Chen HC, Khan MA, Huang FM, Wan XX, et al. Polymorphisms of DNA repair genes XPD, XRCC1, and OGG1, and lung adenocarcinoma susceptibility in Chinese population. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):2843–8. doi:10.​1007/​s13277-013-0844-6.CrossRef
8.
Zurück zum Zitat Yin QH, Liu C, Hu JB, Meng RR, Li L, Wang YJ. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case–control studies. Asian Pac J Cancer Prev : APJCP. 2013;14(1):231–6.PubMedCrossRef Yin QH, Liu C, Hu JB, Meng RR, Li L, Wang YJ. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case–control studies. Asian Pac J Cancer Prev : APJCP. 2013;14(1):231–6.PubMedCrossRef
9.
Zurück zum Zitat Sorour A, Ayad MW, Kassem H. The genotype distribution of the XRCC1, XRCC3, and XPD DNA repair genes and their role for the development of acute myeloblastic leukemia. Genet Test Mol Biomarkers. 2013;17(3):195–201. doi:10.1089/gtmb.2012.0278.PubMedCrossRef Sorour A, Ayad MW, Kassem H. The genotype distribution of the XRCC1, XRCC3, and XPD DNA repair genes and their role for the development of acute myeloblastic leukemia. Genet Test Mol Biomarkers. 2013;17(3):195–201. doi:10.​1089/​gtmb.​2012.​0278.PubMedCrossRef
10.
Zurück zum Zitat Lee KM, Choi JY, Lee JE, Noh DY, Ahn SH, Han W, et al. Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast cancer Res Treat. 2007;106(3):433–8. doi:10.1007/s10549-007-9506-y.PubMedCrossRef Lee KM, Choi JY, Lee JE, Noh DY, Ahn SH, Han W, et al. Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. Breast cancer Res Treat. 2007;106(3):433–8. doi:10.​1007/​s10549-007-9506-y.PubMedCrossRef
11.
12.
Zurück zum Zitat Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, et al. Promoter polymorphism (−786T > C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer. 2006;107(9):2245–53. doi:10.1002/cncr.22269.PubMedCrossRef Lu J, Wei Q, Bondy ML, Yu TK, Li D, Brewster A, et al. Promoter polymorphism (−786T > C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer. 2006;107(9):2245–53. doi:10.​1002/​cncr.​22269.PubMedCrossRef
13.
Zurück zum Zitat Ryk C, Wiklund NP, Nyberg T, de Verdier PJ. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary bladder cancer. Nitric Oxide: Biol Chem / Off J Nitric Oxide Soc. 2011;25(3):338–43. doi:10.1016/j.niox.2011.06.003.CrossRef Ryk C, Wiklund NP, Nyberg T, de Verdier PJ. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary bladder cancer. Nitric Oxide: Biol Chem / Off J Nitric Oxide Soc. 2011;25(3):338–43. doi:10.​1016/​j.​niox.​2011.​06.​003.CrossRef
14.
Zurück zum Zitat Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urologic Oncol. 2013;31(7):1132–40. doi:10.1016/j.urolonc.2012.01.002.CrossRef Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and Intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urologic Oncol. 2013;31(7):1132–40. doi:10.​1016/​j.​urolonc.​2012.​01.​002.CrossRef
15.
Zurück zum Zitat Yeh CC, Santella RM, Hsieh LL, Sung FC, Tang R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer J Int du cancer. 2009;124(7):1565–71. doi:10.1002/ijc.24114.CrossRef Yeh CC, Santella RM, Hsieh LL, Sung FC, Tang R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer J Int du cancer. 2009;124(7):1565–71. doi:10.​1002/​ijc.​24114.CrossRef
16.
Zurück zum Zitat Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramirez-Armengol JA, Moreno Nogueira JA, et al. Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep. 2006;16(2):353–9.PubMed Conde MC, Ramirez-Lorca R, Lopez-Jamar JM, Molero E, Ramirez-Armengol JA, Moreno Nogueira JA, et al. Genetic analysis of caveolin-1 and eNOS genes in colorectal cancer. Oncol Rep. 2006;16(2):353–9.PubMed
17.
Zurück zum Zitat Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R. Vascular invasion in human breast cancer is correlated to T– > 786C polymorphism of NOS3 gene. Nitric oxide : biol chem / off j Nitric Oxide Soci. 2003;9(2):118–22.CrossRef Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R. Vascular invasion in human breast cancer is correlated to T– > 786C polymorphism of NOS3 gene. Nitric oxide : biol chem / off j Nitric Oxide Soci. 2003;9(2):118–22.CrossRef
18.
Zurück zum Zitat Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, et al. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet. 2010;11:167. doi:10.1186/1471-2350-11-167.PubMedCentralPubMedCrossRef Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, et al. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet. 2010;11:167. doi:10.​1186/​1471-2350-11-167.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, Savic-Pavicevic D et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. International journal of experimental pathology. 2013. doi:10.1111/iep.12045 Brankovic A, Brajuskovic G, Nikolic Z, Vukotic V, Cerovic S, Savic-Pavicevic D et al. Endothelial nitric oxide synthase gene polymorphisms and prostate cancer risk in Serbian population. International journal of experimental pathology. 2013. doi:10.​1111/​iep.​12045
22.
Zurück zum Zitat Du L, Wang H, Xiong T, Ma Y, Yang J, Huang J, et al. The polymorphisms in the MGMT gene and the risk of cancer: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):3227–37. doi:10.1007/s13277-013-0893-x.CrossRef Du L, Wang H, Xiong T, Ma Y, Yang J, Huang J, et al. The polymorphisms in the MGMT gene and the risk of cancer: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(5):3227–37. doi:10.​1007/​s13277-013-0893-x.CrossRef
23.
Zurück zum Zitat Huang J, Yang J, Wang H, Xiong T, Zhang H, Ma Y, et al. The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(3):1833–8. doi:10.1007/s13277-013-0724-0.CrossRef Huang J, Yang J, Wang H, Xiong T, Zhang H, Ma Y, et al. The association between the poly(A) polymorphism in the VDR gene and cancer risk: a meta-analysis. Tumor Biol: J Int Soc Oncodev Biol Med. 2013;34(3):1833–8. doi:10.​1007/​s13277-013-0724-0.CrossRef
Metadaten
Titel
The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk
verfasst von
Yonggang Zhang
Qingyi Jia
Pei Xue
Yuqi Liu
Tianyuan Xiong
Jiqiao Yang
Chenxi Song
Qing He
Liang Du
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1467-7

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.